tetano
Editor, Senior Moderator
Transplant Direct
. 2021 Dec 23;8(1):e1248.
doi: 10.1097/TXD.0000000000001248. eCollection 2022 Jan.
Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients
Olivier Marion[SUP] 1 2 3 [/SUP], Arnaud Del Bello[SUP] 1 3 [/SUP], Florence Abravanel[SUP] 2 3 4 [/SUP], Stanislas Faguer[SUP] 1 3 [/SUP], Laure Esposito[SUP] 1 [/SUP], Anne Laure Hebral[SUP] 1 [/SUP], Julie Bellière[SUP] 1 3 [/SUP], Jacques Izopet[SUP] 2 3 4 [/SUP], Nassim Kamar[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Background: A weak immunogenicity has been reported in solid organ transplant (SOT) recipients after 2 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The aim of this retrospective study was to identify the predictive factors for humoral response in SOT patients.
Methods: Three hundred and ninety-three SOT patients from our center with at least 4 wk of follow-up after 2 doses of mRNA-based vaccine were included in this study. Anti-SARS-Cov-2 spike protein antibodies were assessed before and after vaccination.
Results: Anti-SARS-CoV-2 antibodies were detected in 34% of the patients: 33.7% of kidney transplant patients, 47.7% of liver transplant patients, and 14.3% of thoracic transplant patients (P = 0.005). Independent predictive factors for humoral response after vaccination were male gender, a longer period between transplantation and vaccination, liver transplant recipients, a higher lymphocyte count at baseline, a higher estimated glomerular filtration rate and receiving the tacrolimus + everolimus ± steroids combination. Conversely, the nondevelopment of anti-SARS-CoV-2 antibodies after vaccination was associated with younger patients, thoracic organ recipients, induction therapy recipients, and tacrolimus + mycophenolic acid ± steroids recipients.
Conclusions: The immunosuppressive regimen is a modifiable predictive factor for humoral response to SARS-CoV-2 vaccine.
. 2021 Dec 23;8(1):e1248.
doi: 10.1097/TXD.0000000000001248. eCollection 2022 Jan.
Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients
Olivier Marion[SUP] 1 2 3 [/SUP], Arnaud Del Bello[SUP] 1 3 [/SUP], Florence Abravanel[SUP] 2 3 4 [/SUP], Stanislas Faguer[SUP] 1 3 [/SUP], Laure Esposito[SUP] 1 [/SUP], Anne Laure Hebral[SUP] 1 [/SUP], Julie Bellière[SUP] 1 3 [/SUP], Jacques Izopet[SUP] 2 3 4 [/SUP], Nassim Kamar[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 34966837
- PMCID: PMC8710345
- DOI: 10.1097/TXD.0000000000001248
Abstract
Background: A weak immunogenicity has been reported in solid organ transplant (SOT) recipients after 2 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The aim of this retrospective study was to identify the predictive factors for humoral response in SOT patients.
Methods: Three hundred and ninety-three SOT patients from our center with at least 4 wk of follow-up after 2 doses of mRNA-based vaccine were included in this study. Anti-SARS-Cov-2 spike protein antibodies were assessed before and after vaccination.
Results: Anti-SARS-CoV-2 antibodies were detected in 34% of the patients: 33.7% of kidney transplant patients, 47.7% of liver transplant patients, and 14.3% of thoracic transplant patients (P = 0.005). Independent predictive factors for humoral response after vaccination were male gender, a longer period between transplantation and vaccination, liver transplant recipients, a higher lymphocyte count at baseline, a higher estimated glomerular filtration rate and receiving the tacrolimus + everolimus ± steroids combination. Conversely, the nondevelopment of anti-SARS-CoV-2 antibodies after vaccination was associated with younger patients, thoracic organ recipients, induction therapy recipients, and tacrolimus + mycophenolic acid ± steroids recipients.
Conclusions: The immunosuppressive regimen is a modifiable predictive factor for humoral response to SARS-CoV-2 vaccine.